

Global Parkinson's Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson's disease

Supplementary Information

Contents

| | |
|---|-----------|
| 1. GP2 Consent Guidelines and Recommended Language | 1 |
| 2. Clinical Cohort Meta-Data | 5 |
| 3. GitHub Links | 5 |
| 4. Cohort Site Interest Form | 5 |
| 5. Map of contributing cohorts and genotyping tracker | 21 |
| 6. Contributing Institutions | 21 |
| 7. Sample preparation and shipment guidelines for genotyping at NIH, Maryland, USA | 22 |
| 8. Sample preparation and shipment guidelines for genotyping at Fulgent, California, USA. | 24 |
| 9. Sample preparation and shipment guidelines for genotyping at DZNE, Tübingen, Germany. | 26 |

1. GP2 Consent Guidelines and Recommended Language

The GP2 Consent Guidelines and Recommended Language can be viewed and downloaded at <https://gp2.org/resources/consent-guidelines/>. The current guidelines (Version October 2020) are below.

Consent Guidelines & Recommended Language

Summary

The Global Parkinson's Genetics Program (GP2) has developed the following template text to assist researchers who wish to submit samples and/or data to GP2. The template text is intended as a guide, and it can be adapted to reflect local requirements. However, the content should remain true to the goal of international data sharing. When developing your consent document, please be sure to include any additional content required by your local ethics review board which may not be listed below.

Introduction

If not consenting as part of another study: You are invited to take part in the Global Parkinson's Genetics Program (GP2). This is a research project. Researchers from around the world are collaborating through this project to study the genetics of Parkinson's Disease. GP2 includes people with and without Parkinson's Disease. You can find information about GP2 and the researchers leading the program at www.gp2.org.

At [name of institution], this project is being led by [name of investigator]. All research that uses peoples' personal data must be reviewed by an ethics board or committee. This project has been approved by [ethics board/committee information]. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and The Michael J. Fox Foundation for Parkinson's Research.

If consenting as part of another study: You are invited to take part in [name of study]. This is a research project. [Explain the purpose of this study. Provide details regarding the institution(s), investigator(s), and ethics board review.]

[Name of study] is collaborating with researchers from around the world through the Global Parkinson's Genetics Program (GP2) to study the genetics of Parkinson's Disease. GP2 includes people with and without Parkinson's Disease. You can find more information about GP2 and the researchers leading the program at www.gp2.org.

Voluntariness

Your participation in this study is voluntary. The decision about whether or not to participate is completely up to you. If you choose not to participate in the study, your choice will not affect your medical care.

Research activities

If not consenting as part of another study: If you choose to participate, you will be asked to provide a small sample (less than a tablespoon) of blood [or saliva]. You will also be asked questions about your health and your family history of Parkinson's Disease.

If consenting as part of another study: [Explain the activities involved in this study. Include the collection of a blood or saliva sample for DNA.]

Payment for Participation

[GP2 will not provide payment for participation. If subjects will be reimbursed for time/inconvenience related to your research activities, please specify.]

[For US studies, specify cost/no-cost to participate.]

For more information check the Global Parkinson's Genetics Program (GP2) website www.gp2.org or email info@gp2.org

Define the research data – genomic and personal data

Your sample will be used to generate genomic data. Genes are the basic 'instruction book' for the cells that make up our bodies. Genes are made out of DNA, and all of the DNA in each cell is called the genome. Although our DNA is very similar to each other, your genomic data is entirely unique.

Other types of data about you will also be collected. This may include information about your sex, age, ethnicity, and diseases or syndromes you may have.

Data coding (or pseudonymization)

Information that directly identifies you, such as your name, will be replaced with a 'code' or 'ID number.' Your name and other identifying information will not be shared with other researchers.

Describe future use

Your samples and data will be used to learn about the genetic differences between people with and without disease. They may also be used in additional research studies involving PD, other neurological conditions, other types of disorders, or other biomedical research studies. These additional studies may involve development of cures, therapies and products and services for the benefit of PD and other patients.

Explain international sharing

This research may be conducted anywhere in the world; the researchers studying your samples and data may be located outside your country. These projects can also take place in universities, hospitals, nonprofit groups, for-profit companies, or government laboratories.

Include commercial/non-academic use

Your sample and data are a gift for research. The future research projects may take place in universities, hospitals, nonprofit groups, for-profit companies, or government laboratories.

Some of the research done with your information may one day lead to new software, tests, drugs, or other commercial products. If this happens, you will not receive any of the profits from these new products.

Explain managed access (and unrestricted access for aggregate data)

Your coded data, will be stored on a secured data platform. Information in this data platform can only be accessed and used by researchers who have been granted formal approval to access data and who have signed agreements to protect the confidentiality of the information. The access agreements also require researchers to respect the laws and ethical guidelines for scientific research.

Your coded data may also be combined with data from many thousands of other people in large-scale analyses. A summary of this data may be made public (openly accessible) to anyone without restriction.

Include storage on cloud servers

Your coded data will be stored on one or more data platforms coordinated by multiple institutions that can be used by researchers around the world. These researchers may be conducting their own projects or may be working on projects coordinated by the sponsors.

The data platform may be hosted on commercial cloud servers. The cloud refers to software and services that run on the Internet, instead of on a specific computer. These cloud servers meet international security and safety standards.

Do not limit duration of storage

Preferred: Your coded samples and/or data will be stored indefinitely or until they are withdrawn or no longer useful for current or future research.

If indefinite storage is not allowed: Your coded samples and/or data may be stored and used for research for 30 (thirty) years.

Explain data withdrawal

You may withdraw consent for research use of your samples and data at any time. If you choose to withdraw, your samples will be destroyed, and your data will be removed from the data platform. However, it may not be possible to retrieve data that has already been distributed for research use.

Request consent to contact the participant for future research

With your permission, we may re-contact you to invite you to provide additional data or to be involved in new research projects.

[Please verify requirements for consent to recontact with your ethics board].

Discuss lack of benefit and risk of re-identification

You will not benefit personally from sharing your data. Participating in the study may help researchers in many areas of scientific research, such as health and genetics.

Your information will be coded, which means it will not be connected to any information that directly identifies you, such as your name, address, and contact information. However, it is very difficult to make genetic information completely anonymous. There is a risk that people that have your information could try to connect it to your identity by combining it with other personal information about you, through a process called re-identification. Also, in the future, new technologies could be developed that make it easier to connect your genetic information to your identity. The risks related to re-identification are difficult to predict at this time.

Because genetic information is shared among people who are biologically related to you, it is possible that information about your family members could also be revealed.

There is always a risk that information from genetic studies might be used to make certain statements or conclusions about groups or communities. In some cases, this can lead to discrimination against individuals, families, groups or communities.

Contacts

[Provide contact information for both local study staff and the regulatory/ethics authority.]

2. Clinical Cohort Meta-Data

GP2 is collecting information regarding other biosample and data types that are available for contributing cohorts. These samples/data will not be requested or shared by GP2. The information is intended to allow investigators to identify collaborators with similar interests and available data for auxiliary studies e.g., biomarker or imaging studies. The below table gives an indication of the availability of these data/sample types as of May 15th 2022.

| Data/sample modality | Number of cohorts with available data/samples |
|---------------------------------|---|
| MRI | 43 |
| DAT Scan | 34 |
| Plasma | 57 |
| Serum | 55 |
| RNA | 28 |
| PBL | 21 |
| LCL | 3 |
| CSF | 24 |
| Skin Biopsy | 22 |
| iPS | 15 |
| Post-mortem Brain Tissue | 15 |

3. GitHub Links

Global Parkinson's Genetics Program – Code (Main GP2 repository):
<https://github.com/GP2code>

Neuro Booster Array:
[https://github.com/GP2code/Neuro Booster Array](https://github.com/GP2code/Neuro_Booster_Array)

4. Cohort Site Interest Form

Below is a blank copy of the Site Interest Form that cohort Investigators are asked to complete to register their interest in joining GP2. The submitted form is reviewed by the Cohort Integration Working Group to determine whether the cohort should be included. The numbers entered into the form can be approximate; it is intended to provide an overview of the cohort and samples/data availability. Investigators who are interested in joining GP2 can complete the live form here:
<https://forms.gle/tAEfZHu94jpu8g6i9>

GP2 complex trait group: Site Interest Form (Version 2)

Thank you for your interest in collaboration. We would like to ask some general questions about your cohort, number of available (will be available) data and samples, genotyping chips, and IRB approved information especially for data sharing policies. The form consists of 8 sections and will take 20 minutes to fill in. You can edit the input after you submit it. If you have any questions please contact gp2cohort@parkinsonsroadmap.org.

***Required**

1. Email *

2. NAME *

3. INSTITUTION *

4. SHORT NAME OF STUDY *

5. FULL NAME OF STUDY *

6. PI *

7. email *

8. Year Started *

9. Year Completed *

10. FOLLOW UP COMPLETED *

4-digit, 9999 if the end is not planned

11. Is this a multi-site study? *

Mark only one oval.

Yes

No

12. What is the main setting of the study (main location of recruitment)? *

13. Who are the participants? *

Tick all that apply.

PD only

PD cases and controls

Defined PD group, e.g. early onset PD, familial PD, DBS

Other: _____

14. What is the study context? *

Mark only one oval.

- Observational study
- Interventional study e.g. drug trial

15. What is the study timespan? *

Mark only one oval.

- Cross-sectional: one assessment only, with no further contact
- Cross-sectional plus: one assessment with further questionnaires, EPR, Mortality follow-up
- Longitudinal (prospective): multiple face-to-face assessments
- Longitudinal (retrospective)

16. Planned follow-up duration and visit intervals

e.g. 5 years and every 6 month. (Skip this question if not longitudinal)

17. Main Study Site Region *

Mark only one oval.

- North America
- South America
- Europe
- Africa
- Asia/Oceania
- No main region but multi-region

18. Country of main site *

19. Publication DOI or webpage describing study design

Study Participants

20. Rough breakdown of ancestry - Europeans (%) *

Among those with blood/DNA samples

21. Rough breakdown of ancestry - Africans (%) *

Among those with blood/DNA samples

22. Rough breakdown of ancestry - Asians (%) *

Among those with blood/DNA samples

23. Inclusion criteria: what criteria was used to confirm/diagnose PD cases?

Mark only one oval.

MDS Diagnostic criteria

UK Brain Bank criteria

Other: _____

24. Inclusion criteria: what are the disease stage criteria for recruiting PD cases?

E.g. diagnosis < 5 years, symptom onset < 3 years, Hoehn and Yahr stage < 3, no medication etc.

25. Inclusion criteria: are there any other important criteria for PD cases?

E.g. MMSE<27, no family history etc.

26. What are the inclusion criteria for controls?

27. Are there any other specific recruitment features?

28. What is the percentage (%) with post-mortem confirmation of diagnosis? *

0 - 100

Genotyping
information

Please answer the following questions if genotyping has done/planned. Depending on the coverage of the genotyping chip, GP2 may not need to re-genotype the samples. Please put NA if the genotyping has not been done/planned.

29. Name and version of genotyping chip if used *

"NA" if genotyping has not been done/planned.

30. Number of SNPs on the chip *

Rough number is fine (e.g. 230K, 510K, 1M). "NA" if genotype has not been done/planned.

Currently available data
and samples

For the following questions, please answer based on the current
availability of data/samples.

31. Number of participants with PD *

Those with the clinical data available and transferrable.

32. Number of PD patients whose DNA is currently available *

If DNA are not extracted from specimen, please DO NOT include them here.

33. Number of PD patients whose genotype is currently available *

If genotyping has been done and can be transferred to NIA. 0 otherwise

34. Number of participants without PD *

Those with the clinical data available and transferrable.

35. Number of non-PD participants whose DNA is currently available *

If DNA are not extracted from specimen, please DO NOT include them here but include them in the
following question

36. Number of non-PD participants whose genotype is currently available *

37. Shipping current DNA samples *

Samples are going to be genotyped at NIH with a custom array for neurodegenerative disorders. Data and samples will be returned to submitting sites. If it is impossible to send DNA samples to NIH, please check the box below. This will be subject to MTA and collaborative agreements but an initial indication of the situation for your study will be helpful

Mark only one oval.

- We anticipate we will be able to send samples to NIH for genotyping
- We anticipate we will not be able to send samples to NIH for genotyping
- We do not know the situation with transferring samples at this time
- NIH(NIA) should have had all the DNA samples already
- Other: _____

Additional
data/sample
expected to be
available by the
end of 2022

NIA needs to receive samples by the end of 2022 at the latest. For the ongoing study, please provide your best guess about the additional availability of data and samples by the end of 2022. For the completed study, please provide 0 for all questions in this section.

38. Number of ADDITIONAL PD patients *

39. Number of ADDITIONAL PD patients whose DNA will be available by the end of 2022 *

Can Include participants with blood/specimen but DNA have not been extracted yet

40. Number of ADDITIONAL PD patients whose genotype will be available by the end of 2022 *

41. Number of ADDITIONAL non-PD patients *

42. Number of ADDITIONAL non-PD participants whose DNA will be available by the end of 2022 *

Can Include participants with blood/specimen but whose DNA has not been extracted yet

43. Number of ADDITIONAL non-PD participants whose genotype will be available by the end of 2022 *

44. Shipping ADDITIONAL DNA samples

Mark only one oval.

- We anticipate we will be able to send samples to NIH for genotyping
- We anticipate we will not be able to send samples to NIH for genotyping
- We do not know the situation with transferring samples at this time
- Other: _____

Ethics Approval for Use of Data & Samples

45. Institutional Review/Ethics Review Board

Which ethics committee reviewed and approved this human subjects research?

46. Date of ethics board approval

Example: 7 January 2019

47. Data Sharing *

What are the terms of data sharing outlined in the consent documents?

Mark only one oval.

- Use limited to study for which they were originally collected
- Use limited to PI/Institution at which study was conducted
- Use limited to Parkinson's Disease research
- Consent silent on future use
- Consent explicitly allows sharing of data
- Other: _____

48. Sample Sharing *

What are the terms of sample sharing outlined in the consent documents?

Mark only one oval.

- Use limited to study for which they were originally collected
- Use limited to PI/Institution at which study was conducted
- Use limited to Parkinson's Disease research
- Consent silent on future use
- Consent explicitly allows sharing of samples
- Other: _____

49. International Sharing *

Does the consent allow sharing of data and/or samples outside of the country in which the study was performed?

Mark only one oval.

- No
- Consent silent on international sharing/storage
- Yes
- Other: _____

50. Commercial Use *

Does the consent allow for commercial use of the samples/data?

Mark only one oval.

- No
- Consent silent on commercial use
- Yes
- Other: _____

51. Data Storage Location *

Does the consent form specify where data will be stored?

Mark only one oval.

- Storage location specified in consent
- Consent silent on storage location
- Consent allows storage outside the institution and/or on cloud servers
- Other: _____

52. Duration of Storage *

Is the duration of data storage limited?

Mark only one oval.

- Limited
- Consent silent on duration of storage
- Unlimited
- Other: _____

53. If storage duration is limited, when does it expire?

Example: 7 January 2019

Collected Data

54. Basic clinical variables available for most participants - multiple responses are possible

Tick all that apply.

- Gender/sex
- Age at diagnosis
- Age at onset
- Censored vital status (Alive/Dead with Date)
- Family history of PD (Basic - present/absent)
- Family history (Detailed - structure, number of affected family members, c/w AD/AR/X-linked)
- Education level
- Self-reporting race
- Medical history (common/PD related diseases)
- Diagnostic certainty
- Time to major PD events (e.g., HY3, wearing-off, dyskinesia)
- Diagnosis checklist (MDS diagnostic criteria)

55. Other samples available for some participants

Tick all that apply.

- Plasma
- Serum
- RNA
- PBL (Peripheral blood lymphocytes)
- LCL (Lymphoblastoid cell lines)
- Skin biopsy
- iPS
- Post-mortem brain
- CSF

56. *Omics Data Availability

Tick all that apply.

| | Blood | Brain | Other Tissues |
|-----------------------------|--------------------------|--------------------------|--------------------------|
| RNAseq | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Methylation | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Metabolomics | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Proteomics | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Exome/Genome sequence files | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

57. Clinical Data Availability *

Mark only one oval per row.

| | Cross-sectional | Longitudinal | None |
|--|-----------------------|-----------------------|-----------------------|
| Medication information | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Global PD severity (e.g. CISI-PD) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Lifestyle (smoking, alcohol, income) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Environment (residence, work) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Head trauma history | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Hoehn and Yahr | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| UPDRS (original/MDS) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Cognitive measurements | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| REM sleep behavior disorder | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Autonomic function | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Depression/anxiety measurement | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Sleep assessment | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Vitals (Height, weight, BMI, BP) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Orthostatic hypotension | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Smell assessment | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Activities of daily living (e.g. Schwab & England) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Quality of life (e.g. PDQ39/PDQ8) | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Pain assessment | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| Blood CBC, Chem | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |

58. Imaging data availability *

Mark only one oval per row.

| | Cross-sectional | Longitudinal | None |
|---------|-----------------------|-----------------------|-----------------------|
| MRI | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |
| DATSCAN | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |

59. Pathology availability *

Is pathology available for more than half (PD) participants?

Mark only one oval.

- Yes
 No

60. Free note (describe any additional data types you can provide)

61. Are you able to recontact patients if available for further follow-up/research studies? *

Mark only one oval.

- Yes
 No

Additional questions

62. Are you also interested in joining the GP2 monogenic hub?

The GP2 monogenic hub will collate possible monogenic cases. If you are interested, please indicate here and you will be recontacted by the Monogenic team

Mark only one oval.

Yes

No

63. In publication for research using GP2 data, do you support:

Transparency, Collaboration, and Open Science is GP2's policy goal. We would like to know your general position on this. Multiple responses possible

Tick all that apply.

Open data

Open code (analytical scripts)

Publishing with CC-BY license AND immediate free access through PubMed Central

64. Would you like to request analytical support from the GP2 data analysis team?

Tick all that apply.

Yes

Not sure

No

65. Please send the consent form, protocol and case report form to

cohort@gp2.org

And any comments here.

5. Map of contributing cohorts and genotyping tracker

Below is a map of the geographic distribution of cohorts and the progress of genotyping (as of 15th May 2022). The live map is regularly updated and can be viewed on the GP2 website at <https://gp2.org/cohort-dashboard/>.



6. Contributing Institutions

Details of institutions contributing PD cohorts to GP2 can be found on the GP2 webpage at <https://gp2.org/members/>

7. Sample preparation and shipment guidelines for genotyping at NIH, Maryland, USA

Requirements for shipment of samples to NIH for GP2 genotyping

The Global Parkinson's Genetics Program (GP2) aims to genotype over 150,000 samples. The array of choice is the Illumina Infinium Global Diversity Array (GDA). This array is built on a high-density (1.9M total variants) single nucleotide polymorphism (SNP) global backbone optimized for cross-population imputation coverage of the human genome. In addition, a ~80K custom content (NeuroBooster, [GitHub link](#)) is added including: 1) known causal variants for various neurodegenerative diseases 2) imputation boosters for underrepresented populations. More information on the GDA array can be found here: <https://www.illumina.com/products/by-type/microarray-kits/infinium-global-diversity.html>

DNA requirements:

- **Concentration:** 50ng/uL or greater, preferably measured with a Qubit (diluted in molecular grade water)
- **Quantity:** 1ug or more
- **Quality:** 260/280 ratio of ~1.8
- Final DNA concentration should be verified with Nanodrop or Qubit
- DNA should be aliquoted in screw-top 1.5~2ml microcentrifuge tubes.
- Label tubes clearly with the local sample ID and the submitter (PI, Institution).
- DNA aliquots may be shipped in plates only with prior approval -or- if DNA plates are prepared by a biorepository (Please contact [Dena Hernandez](#) for this)
 - All wells are filled in th 96-well plate
 - Should not have any empty wells except for the last plate

DNA Sample Manifest:

- **In advance of shipment**, please email the electronic DNA Sample manifest to Yeajin Song <yeajin@datatecnica.com> and cohort@gp2.org
- Use this [DNA Sample Manifest template](#).
- You will be issued a GP2 study_code to identify your cohort. Please ask if you haven't received one.
- Your Sample Manifest will be reviewed and QC'd by CIWG.
- **After** you receive the QC'd manifest back you can arrange the shipment.


Shipping Instructions:

- The GP2 study_code should be included in the first line of the delivery address (see below).
- Seal the microcentrifuge tubes containing your DNA with parafilm.
- Place the sealed microcentrifuge tubes in a small solid box for additional insulation during shipment. (Example [here](#)).
- To prevent sample tubes from moving during shipment, fill any remaining space in the box with clean tissue paper and/or bubble wrap prior to sealing.
- Include a printed copy of the DNA Sample Manifest in the shipment box with the samples (the QC'd version that was returned to you).
- Samples should be shipped with sufficient dry ice.
- Stick the dry ice label ([here](#)) to your outer box, or customs may refuse/delay the shipment.
- Label your outer box with the words "EXEMPT HUMAN SPECIMEN". Letter height should be at least 8mm. (Non-infectious, non-hazardous human specimens).
- Ensure the outer box is clearly labelled with the sender and receiver addresses.
- Ship the samples with FedEx. Email hernand@nih.gov or cohort@gp2.org for the FedEx account number.
- Ship on a Monday or Tuesday.

Following receipt of your sample manifest, a specific GP2 code will be issued. This code should be included on the first line of the shipping address as below.

Shipping address:

Dena G. Hernandez_(specific GP2 study code)
Laboratory of Neurogenetics
National Institute on Aging, National Institutes of Health
Building 35, Room 1A215, 35 Convent Drive
Bethesda, MD 20892, USA

 001 301 312 5871

8. Sample preparation and shipment guidelines for genotyping at Fulgent, California, USA.

Requirements for shipment of samples to Fulgent for GP2 genotyping

The Global Parkinson's Genetics Program (GP2) aims to genotype over 150,000 samples. The array of choice is the Illumina Infinium Global Diversity Array (GDA). This array is built on a high-density (1.9M total variants) single nucleotide polymorphism (SNP) global backbone optimized for cross-population imputation coverage of the human genome. In addition, a ~80K custom content (NeuroBooster, [GitHub link](#)) is added including: 1) known causal variants for various neurodegenerative diseases 2) imputation boosters for underrepresented populations. More information on the GDA array can be found here: <https://www.illumina.com/products/by-type/microarray-kits/infinium-global-diversity.html>

DNA requirements:

- **Concentration:** 50ng/uL or greater, preferably measured with a Qubit (diluted in molecular grade water)
- **Quantity:** 1ug or more
- **Quality:** 260/280 ratio of ~1.8
- Final DNA concentration should be verified with Nanodrop or Qubit
- DNA aliquots may be shipped in plates if the plates are well sealed.
 - Assign each plate a unique ID or barcode, and ensure the sample positions specified in your sample manifest are correct.
- DNA aliquots can alternatively be shipped in 1.5 or 2ml screw-top tubes.
 - Label tubes clearly with the local sample ID and the submitter (PI, Institution).

IMPORTANT: Fulgent process the samples in batches of 48, and will charge GP2 for 48 samples even if a batch contains <48 samples. **Therefore, please only send samples to Fulgent in multiples of 48.** If you are planning to send more samples in the future, you can include any additional samples in your next shipment. If you have finished collecting samples and don't have enough to make up the last batch of 48, please email cohort@gp2.org and let us know how many additional samples you have.

1. DNA Sample Manifest:

- **In advance of shipment**, please complete the [DNA Sample Manifest template](#) (dictionary on second sheet).
- You will be issued a GP2 study_code to identify your cohort. Please ask if you haven't received one (first column in the manifest template).
- Email the completed manifest to Manuela Tan (manuela.tan@ucl.ac.uk) and cohort@gp2.org
- Your sample manifest will be reviewed and QC'ed by the Cohort Integration Working Group (CIWG).
- You will receive your finalised sample manifest back, as well as a second Fulgent Sample Manifest that you will need to print and include in the box with your samples. **After** you have received these manifests from the CIWG, you can arrange shipment of your samples.

2. Sample shipment:

- If you have aliquoted your DNA in plates, ensure the plates are well sealed and each plate has a unique ID.
- If you have aliquoted your DNA in 1.5 or 2mL microcentrifuge tubes, seal the tubes with parafilm. Place the sealed tubes in a small solid box for additional protection during shipment. (Example [here](#)). To prevent sample tubes from moving during shipment, fill any remaining space in the box with clean tissue paper and/or bubble wrap prior to sealing.

- Include a printed copy of the Fulgent Sample Manifest in the shipment box with your samples (the second manifest that was sent to you when your QC'ed sample manifest was returned).
- Ship the DNA samples with cold-packs (dry-ice is not necessary).
- Label your outer box with the words "EXEMPT HUMAN SPECIMEN". Letter height should be at least 8mm. (Non-infectious, non-hazardous human specimens).
- Ensure the outer box is clearly labelled with the sender and delivery addresses.
- The GP2 study_code should be included in the first line of the delivery address (see below).
- Ship the samples with FedEx. Email cohort@gp2.org for the FedEx account number.
- **Ship on a Monday or Tuesday.**
- When your shipment is arranged, email SeqService@fulgentgenetics.com and rblake@fulgentgenetics.com (Rachel Blake) to notify them that you are sending a shipment of samples for genotyping as part of the GP2 initiative. Include your tracking number and a copy of the Fulgent Sample Manifest with your email.

Shipping address:

Rachel Blake (GP2 study: "study_code")
Fulgent Genetics
4978 Santa Anita Avenue, Suite 205
Temple City, California 91780
United States of America

rblake@fulgentgenetics.com
Office: 626.350.0537
Fax: 626.454.1667
Cell: 626.238.4677

9. Sample preparation and shipment guidelines for genotyping at DZNE, Tübingen, Germany.

Instructions for shipment of samples to DZNE for GP2 genotyping

The Global Parkinson's Genetics Program (GP2) aims to genotype over 150,000 samples. The array of choice is the Illumina Infinium Global Diversity Array (GDA). This array is built on a high-density (1.9M total variants) single nucleotide polymorphism (SNP) global backbone optimized for cross-population imputation coverage of the human genome. In addition, a ~80K custom content (NeuroBooster, [GitHub link](#)) is added including: 1) known causal variants for various neurodegenerative diseases 2) imputation boosters for underrepresented populations. More information on the GDA array can be found here: <https://www.illumina.com/products/by-type/microarray-kits/infinium-global-diversity.html>

DNA requirements:

- **Concentration:** 50ng/ul-100ng/ul preferably measured with a Qubit
- **Quantity:** 1ug or more
- **Quality:** 260/280 ratio of ~1.8
- Final DNA concentration should be verified with Nanodrop or Qubit
- DNA for all the samples if feasible or for a subset should be visualised on gel: some degradation is tolerated, but extensively degraded material may not perform well in the assay.
- Samples should be resuspended in water, or 10 mM Tris 8.0, Qiagen EB (10 mM Tris 8.5), or low TE

- DNA aliquots may be shipped in plates if the plates are well sealed.
 - All wells are filled in the 96-well plate
 - Should not have any empty wells except for the last plate
 - Please assign to each plate a unique ID or barcode
- DNA aliquots can alternatively be shipped in 1,5 or 2ml screw-top tubes with sample's ID clearly indicated.

DNA Sample Manifest:

- **In advance of shipment**, please email the electronic DNA Sample manifest to manuela.tan@ucl.ac.uk and cohort@gp2.org
- Use this [DNA Sample Manifest template](#).
- Your Sample Manifest will be reviewed and QC'd by the cohort integration working group (CIWG).
- You will be issued a GP2 study_code to identify your cohort. Please ask if you haven't received one.
- **After** you receive the QC'd manifest back you can arrange the shipment

Shipping Instructions:

- The GP2 study_code should be included in the first line of the delivery address (see below).
- Ship the samples with FedEx. Email patrizia.rizzu@dzne.de for the FedEx account number before shipping.
- If you have aliquoted your DNA in plates, ensure the plates are well sealed and each plate has a unique ID.
- If you have aliquoted your DNA in microcentrifuge tubes, seal the tubes with parafilm. Place the sealed microcentrifuge tubes in a small solid box for additional insulation during shipment. (Example [here](#)). To prevent sample tubes from moving during shipment, fill any remaining space in the box with clean tissue paper and/or bubble wrap prior to sealing.
- Include a printed copy of the DNA Sample Manifest in the shipment box with the samples (**the QC'd version that was returned to you**).

- Samples should be shipped with sufficient dry ice. Stick the dry ice label ([here](#)) to your outer box, or customs may refuse/delay the shipment.
- Label your outer box with the words "EXEMPT HUMAN SPECIMEN". Letter height should be at least 8mm. (Non-infectious, non-hazardous human specimens).
- Ensure the outer box is clearly labelled with the sender and receiver addresses.

- Ship on a Monday or Tuesday.
- Email Patrizia Rizzu patrizia.rizzu@dzne.de a copy of the finalised sample manifest, and include the tracking number and expected delivery time once the shipment is arranged.

Following receipt of your sample manifest, a specific GP2 code will be issued. This code should be included on the first line of the shipping address as below.

Shipping address:

Patrizia Rizzu (specific GP2 code)
DZNE
Applied Genomics for Neurodegenerative Diseases
Otfried Muellerstrasse 23, 7th floor
Tuebingen 72076
Germany
Tel 004970719254082